CG
GPCR icon

Cutler Group’s Structure Therapeutics GPCR Stock Holding History

Cutler Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$159K Buy
23,100
+6,600
+40% +$278K 0.05% 332
2023
Q4 		$91K Buy
+16,500
New +$946K 0.01% 1099

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cutler Group's GPCR Position: Q1 2024 in Review

Cutler Group increased its Structure Therapeutics (GPCR) stake by 16% in Q1 2024, buying an estimated $33.7K and bringing the position to 5,900 shares worth $252K. The position accounts for 0.08% of the portfolio, ranked #240.

Cutler Group first reported a position in GPCR in Q4 2023 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

  • Cutler Group held 5,900 shares of Structure Therapeutics worth $252K as of Q1 2024.
  • Cutler Group bought 800 Structure Therapeutics shares in Q1 2024, an estimated $33.7K.
  • Structure Therapeutics made up 0.08% of Cutler Group's portfolio in Q1 2024, its #240 holding.
  • Cutler Group first reported a position in Structure Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.